Genenta Science presents preliminary Phase 1/2 trial data demonstrating successful reprogramming of GBM tumor microenvironment, showing no dose-limiting toxicity for Temferon and detectable differentiated cells in blood.

Genenta Science, a clinical-stage immuno-oncology company, has presented preliminary data from its ongoing Phase 1/2 clinical trial, demonstrating the successful reprogramming of the tumor microenvironment in glioblastoma (GBM) patients. This is a significant achievement, as it paves the way for innovative treatments of solid tumors. The preliminary data indicates no dose-limiting toxicities related to Temferon, and Temferon-derived differentiated cells were detectable within the peripheral blood, suggesting a promising therapeutic potential.

February 08, 2024
6 Articles

Further Reading